|Bid||141.39 x 1000|
|Ask||141.51 x 1100|
|Day's Range||140.31 - 141.80|
|52 Week Range||121.00 - 145.38|
|Beta (5Y Monthly)||0.70|
|PE Ratio (TTM)||26.97|
|Earnings Date||Jan 22, 2020|
|Forward Dividend & Yield||3.80 (2.69%)|
|1y Target Est||150.78|
Sarepta soared after the company gained FDA approval for its muscular dystrophy treatment. Yahoo Finance’s Anjalee Khemlani joins Seana Smith on The Ticker to discuss.
Stocks on Wall Street rose for the first time in four sessions Wednesday. Spurring them higher: President Donald Trump's remarks that trade talks with China were going "very well." Energy stocks led the broad-based rally, pushing the S&P 500 up more than half percent. Edward Jones investment strategist, Nela Richardson: SOUNDBITE: EDWARD JONES INVESTMENT STRATEGIST, NELA RICHARDSON (ENGLISH) SAYING: "Investors should expect more volatility. So more of the same next year. It doesn't wash away with an interim deal or a tweet or a change in rhetoric. What investors should look for is actual change in actions like a removal or roll back of the existing tariffs and no new tariffs." Shares of online travel agency Expedia among the biggest gainers on the S&P 500. Its CEO and finance head resigned after clashing with the board over strategy. Johnson & Johnson helped lift the Dow. The drug maker said recent tests showed its Baby Powder was free of asbestos. Earlier this year, the FDA reported trace amounts of the material in the product. Shares of Alphabet rallied. Google CEO Sundar Pichai will immediately take over as CEO of the parent company now that Larry Page and Sergey Brin are stepping aside.
ISRG stock climbed 20% in 2019 as of mid-December. But Intuitive Surgical stock’s performance lagged other medical technology stocks. So, is it time to take on this robotic surgery stock?
A handful of sickle cell disease treatments and CAR-T therapies that treat cancer have been approved by the Food and Drug Administration in recent years, but a new crop of investigational therapies that would grow those markets is exciting investors.
Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:00 a.m. (Eastern Time) on Wednesday, January 22nd to review fourth-quarter results. Alex Gorsky, Chairman and Chief Executive Officer; Joseph J. Wolk, Executive Vice President, Chief Financial Officer and Christopher DelOrefice, Vice President, Investor Relations will host the call.
Johnson & Johnson Chief Executive Officer Alex Gorsky has declined to appear at a U.S. congressional hearing set for Tuesday on the safety of the company's Baby Powder and other talc-based cosmetics. In an announcement, the House of Representatives Subcommittee on Economic and Consumer Policy said that its efforts to persuade Gorsky to testify included "repeated attempts to accommodate the company" over nearly a month. Democrat Raja Krishnamoorthi, chairman of the House panel investigating concerns about cancer-causing asbestos in cosmetic talc and powders, said he was disappointed Gorsky turned down the invitation.
In an announcement, the House of Representatives Subcommittee on Economic and Consumer Policy said that its efforts to persuade Gorsky to testify included "repeated attempts to accommodate the company" over nearly a month. Democrat Raja Krishnamoorthi, chairman of the House panel investigating concerns about cancer-causing asbestos in cosmetic talc and powders, said he was disappointed Gorsky turned down the invitation. "Mr. Gorsky refuses to speak to the Subcommittee under oath, yet he has not refrained from making multiple public comments on the topic," Krishnamoorthi said in a statement.
It seems that Johnson & Johnson (NYSE: JNJ) has finally started shaking off those heavy legal headwinds. Accusations of tainted baby powder was just the latest chapter in its long book of controversy. Dow's return was 22% return but the result highlights the company's resiliency in the face of heavy negative sentiment and severe legal headwinds.
Shares took off Monday morning after the company reported data at a medical conference over the weekend that relieved investor anxiety over the company’s experimental cancer drug ide-cel.
Johnson & Johnson (NYSE: JNJ) today announced that its Janssen Pharmaceutical Companies will provide up to 200,000 Ebola vaccine regimens to the Republic of Rwanda. This commitment will support a new immunization program led by the Rwanda Government that aims to help protect the country's citizens from the Ebola outbreak in neighboring Democratic Republic of the Congo (DRC). The first batches of Janssen vaccine have been delivered to the country, and further shipments are being organized.
Johnson & Johnson agreed in October to pay $117 million to settle claims with 41 states that it deceptively marketed pelvic mesh implants, but Oregon officials say its offer did not compensate the harm it caused consumers. In late November, the Oregon Department of Justice rejected another settlement offer from J&J. This one would have allowed the company to retain its "ill-gotten gains,” David Hart, a DOJ lawyer, wrote in an email to Johnson & Johnson attorney last week. Instead, Oregon Attorney General Ellen Rosenblum on Wednesday filed a lawsuit against J&J and its subsidiary Ethicon.
The FDA approves Roche's (RHHBY) Tecentriq for expanded use. It grants priority review status to AstraZeneca (AZN) & Merck's (MRK) supplemental applications.
Glaxo (GSK) submits a new drug application to the FDA for its first-in-class attachment inhibitor fostemsavir, which is being evaluated for the treatment of HIV-1 infection.
Johnson & Johnson (NYSE: JNJ) announced today that Hubert Joly, Executive Chairman of Best Buy Co., Inc, and Mark A. Weinberger, Former EY Global Chairman and CEO, have been appointed to its Board of Directors.
Stocks moved modestly on a day in which Democratic leadership in the House confirmed articles of impeachment will be filed against President Trump, indicating the trade relationship with China is a bigger priority for markets than party politics. * The S&P 500 rose 0.15% * The Dow Jones Industrial Average climbed 0.10% today * The Nasdaq Composite advanced 0.05% * Supported by positive analyst chatter, Nike (NYSE:NKE) was the Dow leader today, jumping 2.21%.Talk that President Trump could back off tariffs on Chinese imports set to go into effect on Dec. 15 along with reports that officials from both sides remain engaged in talks lifted stocks today."Chinese officials are in 'close contact' with their American counterparts on negotiations, said Ministry of Commerce spokesman Gao Feng," reports Bloomberg.InvestorPlace - Stock Market News, Stock Advice & Trading TipsStill, not all of the China-related headlines out Thursday were perfect. For example, Treasury Secretary Steven Mnuchin said earlier today he supports China being removed from a World Bank program designed to help smaller, less affluent nations refinance debt. * 7 Retail Stocks to Buy That Dominated Thanksgiving Shopping "Mnuchin added that the selection of former Treasury Undersecretary David Malpass as the World Bank's president earlier this year gives him confidence the institution will revise its practices to make its lending more equitable." according to CNBC.Those comments may have capped stocks' gains today as just 14 of the Dow's 30 members were higher in late trading. Nike Runs Higher On Goldman UpgradeAs noted above, Nike was the best-performing name in the Dow today and an upgrade from Goldman Sachs explains why the stock surged. Nike entered Thursday with a year-to-date gain of 26%, putting it ahead of the S&P 500 and well ahead of the Dow. Goldman Sachs analyst Alexandra Walvis believes the good times can continue next year.She upgraded Nike to "buy" from "neutral" while adding the stock to Goldman's prestigious conviction buy list."Evidence of building pricing power, signs of operating leverage, accelerating shift to differentiated retail, sharply scaling app ecosystem, and a constructive global athletic growth backdrop," said Walvis in a note to clients.The analyst has a $112 price target on Nike, implying upside of about 20%. Happy Holidays With AppleApple (NASDAQ:AAPL) is classified as a technology stock, but it's very much levered to strength in the consumer sector, making it a credible play on the holiday shopping theme. Wall Streets seems to agree with that sentiment.Today, Citigroup analyst Jim Suva reiterated a "buy" rating on Apple, noting that the holiday season offers plenty of catalysts for the stock."This Christmas is different for Apple," said the Citigroup analyst. "Apple's product offerings as well as pricing strategies and recent demand trends augur for a better Christmas quarter compared with last [fiscal] year when Apple negatively preannounced." Good News For This SectorThe healthcare sector, the second-largest group in the S&P 500 behind technology and an important part of the Dow as well, has been getting plenty of attention thanks to a recent resurgence. Dow component UnitedHealth (NYSE:UNH) has been leading that climb and that stock, along with fellow Dow member Johnson & Johnson (NYSE:JNJ) traded higher today.In other words, it was a mixed bag for Dow healthcare stocks on Thursday with Pfizer (NYSE:PFE) trading lower. But don't fret. Healthcare is looking healthy and could be a rewarding defensive play in 2020. * 10 Hot Pot Stocks to Buy "I believe that it's broken out so strongly that even after … it works off that overbought condition, it's going to rally higher … if we do have a big scare on the tariff side. But it also should rally even if the whole market moves up. So it's kind of a win-win situation, again, after a little bit of a breather on the near term," said Matt Maley, chief market strategist at Miller Tabak, of the healthcare sector in a CNBC interview. Bottom LineTwo days in a row of good/no bad news on the trade front is encouraging, but near-term bullishness will be tested tomorrow when the Labor Department delivers the November jobs report before the bell. The ADP private payroll survey out earlier this week was weaker-than-expected, indicating the same could be true of the more Labor Department number.Economists are expecting the addition of 185,000 new jobs last month. If the number comes in well below that level and the October and September numbers are revised lower, Friday could be a rough day for riskier assets.As of this writing, Todd Shriber did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Retail Stocks to Buy That Dominated Thanksgiving Shopping * 6 Manufacturing Stocks to Buy as the Economy Recovers * The 7 Best Cryptocurrencies to Buy as Blockchain Heats Up The post Dow Jones Today: Trade Influenced Stocks More Than Impeachment News appeared first on InvestorPlace.
DOW UPDATE Shares of 3M and Cisco are retreating Thursday morning, sending the Dow Jones Industrial Average into negative territory. Shares of 3M (MMM) and Cisco (CSCO) are contributing to the blue-chip gauge's intraday decline, as the Dow (DJIA) was most recently trading 79 points, or 0.
ABT stock is one of the biggest diversified medical stocks behind Johnson & Johnson and Roche. As it aims for clearance of its Freestyle Libre 2, is it time to buy Abbott stock?
A stockpile of 500,000 doses of Ebola vaccine for emergency use in outbreaks of the deadly fever is being established by the global vaccine alliance GAVI. The plan is for poor and middle-income countries to access the $178 stockpile free of charge, GAVI said on Thursday, while other countries will need to refund the costs. The stockpiling will start with Merck's newly developed Ervebo vaccine, which won regulatory approval last month.
Investors that have been actively engaged with the U.S.-China trade spat for the past several months know there aren't many certainties except that situations can turn on a dime. In other words, stocks can go from dismal days (yesterday) to excellent showings (today) rather rapidly. * The S&P 500 jumped 0.63% * The Dow Jones Industrial Average soared 0.53% * The Nasdaq Composite advanced 0.54% * Industrial conglomerate 3M (NYSE:MMM), a fairly trade-sensitive name, paced the Dow today, gaining about 1.2%On Tuesday, President Trump said a trade deal with China wasn't necessary until after the 2020 presidential election, exuding confidence he'll win a second term and that China needs a resolution much more than the U.S. That stoked speculation that both sides could proceed with punitive tariffs that would only serve to ratchet up hostilities. Wednesday brought a different, more sanguine story.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 of the Best-Performing Conglomerate Stocks of 2019 "Negotiators are getting near an agreement on the amount of tariff relief in a phase-one accord between the world's two largest economies. President Donald Trump said discussions with China are going very well, just a day after downplaying the urgency of a deal," reports Bloomberg.In other good news, U.S. oil inventories declined by more than analysts were expecting, helping Exxon Mobil (NYSE:XOM) and Chevron (NYSE:CVX), the two largest domestic oil companies, join the ranks of the Dow winners.No one, not even President Trump himself, knows what tomorrow will bring on the trade front, but today was the best day of December to this point as 25 of the 30 Dow members were higher in late trading. Diverting BlameAvid readers of this column know that Johnson & Johnson (NYSE:JNJ) has been in hot water for much of this year, disappointing investors along the way, due in large part to litigation risk, be it asbestos or opioid.The stock rallied 1.62% today, putting it in the upper echelon of Dow performers after JNJ said the Food and Drug Administration (FDA) was wrong when it said it found traces of asbestos in its popular baby powder."Our talc is safe and asbestos free, and these 150-plus tests, and the tests we routinely do to ensure the quality and safety of our talc-based products, are consistent with the results from renowned independent research labs over the past 40 years," said JNJ in a statement out Tuesday evening.The company did say that the previously announced recall of Lot 22318RB of Johnson's Baby Powder remains in effect. Speaking Of Healthcare…It was another solid day at the office for managed care provider UnitedHealth (NYSE:UNH) as the stock gained about 1%. An array of analysts were out today boosting price targets on UNH shares, including BMO Securities to $310, Credit Suisse to $320 and Piper Jaffray to $325. Even the average of those targets, which is just over $318, implies significant upside from the $280 area at which UNH currently resides. Careful With CiscoThere were a small amount of Dow Jones losers today, but Cisco Systems (NASDAQ:CSCO) was the worst offender in the group, shedding 0.88%. * The 7 Best Penny Stocks to Buy This old guard tech name has been tumbling for several months and with an almost 6% drop over the past month, the stock is very much in danger of turning red on the year. Bottom Line on the Dow Jones TodayTomorrow is a new day and with it comes the aforementioned potential for new headlines on the trade front, but some market observers believe President Trump's trade musings are minor blips on the radar and won't derail stocks this month."I do not believe that they will follow through with the December tariff," said Peter Boockvar, Bleakley Advisory Group's chief investment officer, said in an interview with CNBC. "If we do not have a [China trade] deal, I think they'll couch it and we're just postponing the tariffs … The administration knows how sensitive we are to the possibility of those extra tariffs particularly hitting the consumer."As of this writing, Todd Shriber did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 Tech Stocks You Wish You'd Bought During 2019 * 5 Under-the-Radar Marijuana Stocks With Over 100% Upside * Watch These 5 STARS Stocks as They Change the Future The post Dow Jones Today: A Trade Redemption Story appeared first on InvestorPlace.